» Articles » PMID: 26166424

Achieving High Seroprevalence Against Polioviruses in Sri Lanka--results from a Serological Survey, 2014

Overview
Publisher Springer
Date 2015 Jul 14
PMID 26166424
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The immunization program in Sri Lanka consistently reaches >90% coverage with oral poliovirus vaccines (OPV), and no polio supplementary vaccination campaigns have been conducted since 2003. We evaluated serological protection against polioviruses in children. A cross-sectional community-based survey was performed in three districts of Sri Lanka (Colombo, Badulla, and Killinochi). Randomly selected children in four age groups (9-11 months, 3-4 years, 7-9 years, and 15 years) were tested for poliovirus neutralizing antibodies. All 400 enrolled children completed the study. The proportion of seropositive children for poliovirus Type 1 and Type 2 was >95% for all age groups; for poliovirus Type 3 it was 95%, 90%, 77%, and 75% in the respective age groups. The vaccination coverage in our sample based on vaccination cards or parental recall was >90% in all age groups. Most Sri Lankan children are serologically protected against polioviruses through routine immunization only. This seroprevalence survey provided baseline data prior to the anticipated addition of inactivated poliovirus vaccine (IPV) into the Sri Lankan immunization program and the switch from trivalent OPV (tOPV) to bivalent OPV (bOPV).

Citing Articles

Nutritional Status Link with Polioseronegativity Among Children from Poliomyelitis Transmission High-Risk Area of the Democratic Republic of the Congo (DRC).

Mwamba G, Nzaji M, Hoff N, Mukadi P, Musene K, Gerber S J Multidiscip Healthc. 2024; 17:1219-1229.

PMID: 38524863 PMC: 10960541. DOI: 10.2147/JMDH.S437351.


Prediction Model with Validation for Polioseronegativity in Malnourished Children from Poliomyelitis Transmission High-Risk Area of the Democratic Republic of the Congo (DRC).

Mwamba G, Kabamba M, Hoff N, Mukadi P, Musene K, Gerber S Pragmat Obs Res. 2023; 14:155-165.

PMID: 38146546 PMC: 10749540. DOI: 10.2147/POR.S437485.


Poliovirus Immunity among Children Aged 6-11 and 36-48 Months in 14 Polio High-Risk Provinces of Afghanistan: A Health-Facility-Based Study.

Soofi S, Martinez M, Farag N, Hendley W, Ehrhardt D, Ahmed I Vaccines (Basel). 2022; 10(10).

PMID: 36298591 PMC: 9610936. DOI: 10.3390/vaccines10101726.


A Survey to Assess Serological Prevalence of Poliovirus Antibodies in Areas With High-Risk for Vaccine-Derived Poliovirus Transmission in Chad.

Gamougam K, Jeyaseelan V, Jones K, Mainou B, Palmer T, Diaha A J Pediatric Infect Dis Soc. 2021; 11(2):55-59.

PMID: 34791366 PMC: 8865003. DOI: 10.1093/jpids/piab103.


Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission-Niger Experience.

Ousmane S, Ibrahim D, Goel A, Hendley W, Mainou B, Palmer T Open Forum Infect Dis. 2021; 8(7):ofab210.

PMID: 34295940 PMC: 8291560. DOI: 10.1093/ofid/ofab210.


References
1.
Sutter R, Suleiman A, Malankar P, Al-Khusaiby S, Mehta F, Clements G . Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med. 2000; 343(11):767-73. DOI: 10.1056/NEJM200009143431103. View

2.
Abbink F, Buisman A, Doornbos G, Woldman J, Kimman T, Spaendonck M . Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005; 191(6):990-9. DOI: 10.1086/427810. View

3.
Kelley P, Petruccelli B, Stehr-Green P, Erickson R, Mason C . The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US Army recruits. JAMA. 1991; 266(19):2724-9. View

4.
Sutter R, Platt L, Mach O, Jafari H, Aylward R . The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014; 210 Suppl 1:S434-8. DOI: 10.1093/infdis/jiu222. View

5.
Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S . The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand. 1984; 12(1):1-10. DOI: 10.1016/s0092-1157(84)80015-3. View